70 likes | 213 Views
Cancer Care Engineering Colorectal Cancer Gabriela Chiorean, M.D. May 27, 2011. Rationale. Perform OMICs of healthy, polyps, cancer Compare OMICs between cancer, polyps and healthy: develop new screening and risk assessment tools
E N D
Cancer Care Engineering Colorectal CancerGabriela Chiorean, M.D. May 27, 2011
Rationale • Perform OMICs of healthy, polyps, cancer • Compare OMICs between cancer, polyps and healthy: develop new screening and risk assessment tools • Analyse changes in OMICs with treatment and correlate with response/toxicity: predictive markers
Schema IUCRO-0221CCE in CRC Blood (Serum) 7 mL red top Metabolomics, vit D S A M P L E S S H I P D R Y I C E • N=810 • Stratification: • Healthy (n=270) • Polyps (n=270) • Cancer (n=270) • stg 1/2 • stg 3 • stg 4 metastatic Blood (Plasma) 21 mL purple top Genomics, lipidomics, glycoproteomics Fresh Tissue 10 mg polyp or 50 mg cancer / 50 mg normal tissue Paraffin-Embedded Tissue MSI, methylation, KRAS, BRAF, p53 8-hr fasting
Samples CollectionHealthy Controls Label specimens Healthy if no polyps/tumor Screening Colonoscopy – GI Clinic Blood Questionnaires N= 5 6/2009 N=74 5/2010 N=109 5/2011
Samples CollectionAdenomatous Polyps Polyps identified Label specimens Polyp Screening Colonoscopy – GI Clinic Blood Questionnaires Tissue procurement/Research specialist -Polyp cut in ½ -Place in tube with no preservative -Freeze at -70oC N= 3 6/2009 N= 65 5/2010 N= 96 5/2011
Samples CollectionCancer Tissue: tumor, normal mucosa Surgery Chemotherapy Follow-up Blood Questionnaires Every 3 months Up to 24 months N= 8 6/2009 N= 34 5/2010 N= 55 5/2011
Sample Acquisition4/2009-5/2011 Cancer total No prior chemo Prior chemo n=55 n=26 n=29 Stage 1 n=6 n=6 0 Stage 2 n=3 n=2 n=1 Stage 3 n=17 n=10 n=7 Stage 4 n=29 n=8 n=21